The Zechner Lab applies molecular and cell biology techniques to investigate how mammalian cells regulate their phosphate homeostasis and sensing using the ubiquitous phosphate transporter PiT1/SLC20A1 as a model.

Ying Lab focuses on the development and clinical translation of soft medical devices, leveraging advanced design and fabrication techniques to tackle critical, unresolved challenges in human health. Current efforts in my lab center on hydrogel bioadhesives, soft medical robots, and ingestible bioelectronics aimed at enabling tissue-interfacing diagnostics and therapeutics in extreme body environments.

Dr. Mizuno's laboratory studies autonomic control of the cardiovascular system, particularly the underlying alterations in circulatory control in type 1 or type 2 diabetes and Alzheimer’s disease.

The Moe Lab specializes in translational pathophysiology that spans from individual molecules, in vitro cell models, in vivo animal models, to metabolic human studies. 

We are dedicated to uncovering how G protein–coupled receptors (GPCRs) regulate metabolism and contribute to health and disease. Our research aims to translate these discoveries into new insights and therapeutic strategies.

Using patient-specific stem cells, tissue engineering, and omics technologies to develop precision medicine for cardiovascular disease.

The Bann Laboratory focuses on discovering novel mechanistic targets to treat heart failure. We aim to identify regulators of cardiac cell fate reprogramming and regeneration as a molecular strategy to repair and heal the heart following injury.

The Singal & Rich research group focuses on generating critical insights to improve the entire spectrum of liver cancer care. Our studies involve assessing and promoting novel practices, imaging, and blood-based biomarkers to improve risk stratification, screening, early detection and outcomes for patients with hepatocellular carcinoma and other primary liver cancers.  

Drapkin Lab investigates the molecular drivers of oncogenesis, metastasis, and chemoresistance in small cell lung cancer (SCLC) to discover new therapeutic targets. 

The Mosley Lab develops and applies innovative genomic and informatics approaches to identify opportunities to use genetic background to inform clinical and public health decision-making, to identify risk factors and biomarkers of disease, and to identify and reduce heath inequities in vulnerable populations.